The time is now: Achieving FH paediatric screening across Europe – The Prague Declaration

Investor logo

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

BEDLINGTON Nicole ABIFADEL Marianne BEGER Birgit BOURBON Mafalda BUENO Héctor CESKA Richard CILLÍKOVÁ Kristýna CIMICKÁ Zdenka DACCORD Magdalena BEAUFORT Carine de DHARMAYAT Kanika I FERENCE Brian A FREIBERGER Tomáš GEANTA Marius GIDDING Samuel S GROŠELJ Urh HALLE Martin JOHNSON Neil NOVAKOVIC Tanja MÁJEK Ondřej PALLIDIS Athanasios PERETTI Noel PINTO Fausto J RAY Kausik Kosh REES Bleddyn REEVE John REINER Željko SANTOS Raul D SCHUNKERT Heribert ŠIKONJA Jaka SOKOLOVIC Milka TOKGÖZOGLU Lale VRABLÍK Michal WIEGMAN Albert GUTIÉRREZ-IBARLUZEA Inaki

Year of publication 2022
Type Article in Periodical
Magazine / Source GMS health innovation and technologies
MU Faculty or unit

Faculty of Medicine

Citation
Web https://www.egms.de/static/en/journals/hta/2022-16/hta000136.shtml
Doi http://dx.doi.org/10.3205/hta000136
Keywords CVD; CVH; EU; EU best practice; Europe; FH; cardiovascular disease; cardiovascular health; children; declaration; familial hypercholesterolaemia; health systems; implementation; prevention; public health; screening
Attached files
Description Familial hypercholesterolaemia (FH) is the most common inherited metabolic disorder characterized by high cholesterol and if left untreated leads to premature cardiovascular disease, such as heart attacks. Treatment that begins early in life, particularly in childhood, is highly efficacious in preventing cardiovascular disease and cost-effective, thus early detection of FH is crucial. However, in Europe, less than 10% of people living with FH are diagnosed and even less receive life-saving treatment. The Prague Declaration is a call to action for national and European Union policymakers and decision-makers and a result of the Czech EU Presidency meeting on FH Paediatric Screening (early detection of inherited high cholesterol) at the Czech Senate in Prague on 6th September 2022. It builds on a considerable body of evidence which was discussed at the Technical Meeting under the auspices of the Slovenian EU Presidency in October 2021. The Prague meeting addressed the outstanding barriers to the systematic implementation of FH paediatric screening across Europe. In this article, we present the key points from the Prague meeting and concrete actions needed to move forward.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.